WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China.
Wuxi Biologics, a global CRDMO service company, recently opened its DP5 facility in Wuxi, China. The facility is the ninth active facility in WuXi Biologics’ global network.
A continuous and steady isolator filling system is available at the DP5 facility, which offers multiple volume options for pre-filled syringes (PFS), including 1 and 2.25 mL long, 1 and 1 mL, and 3 and 2 mL. The maximum filling speed can reach 400 PFS/min to support 17 million syringes of drug products manufacturing every year.
DP5 will enable WuXi Biologics to offer its global partners faster and more robust end-to-end drug product services for their innovative products at various scales and stages due to the increased manufacturing capacity.
“Pre-filled syringes have emerged as one of the fastest-growing choices for biologics dosage form as our partners seek new and more convenient biologics delivery methods. The GMP operation of DP5, our first commercial drug product facility for pre-filled syringes, not only demonstrates our commitment to global partners, but also marks an important milestone for WuXi Biologics to become one of the global leaders in drug product CDMO services. We’ll continue to enable our clients to advance innovative biologics towards clinical trials, regulatory approvals, and commercialization to benefit patients worldwide,” Dr. Chris Chen, CEO of WuXi Biologics mentioned.
About WuXi Biologics
WuXi Biologics is a global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop, and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 10,000 skilled employees in China, the United States, Ireland, Germany, and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development, and manufacturing solutions. As of the end of 2021, WuXi Biologics is supporting over 480 integrated client projects, including nine in commercial manufacturing.